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Abstract
Background: Contrast-induced nephropathy (CIN) is a serious adverse event that certain patients
experience as a result of a radiologic study performed with intravascular contrast media. The most at risk
population includes patients with preexisting renal impairment. Due to the lack of successful treatment for
contrast-induced nephropathy and its potentially critical results, preventative strategies are imperative.
Though many approaches have been implemented, no universal standard protocol currently exists for the
prevention of CIN in at-risk patients. Recent research has demonstrated controversial results of the use of
short-term statin therapy for prevention of CIN. The aim of this systematic review is to evaluate the efficacy of
atorvastatin in prevention of CIN in patients with renal impairment undergoing coronary angiography or
percutaneous coronary intervention.
Methods: An exhaustive search of available medical literature from MEDLINE-Ovid, MEDLINE-PubMed,
and Google Scholar was performed using the search terms “contrast-induced nephropathy,” “acute kidney
injury,” “statins,” “atorvastatin,” “HMG-CoA reductase inhibitors.” Studies were excluded if they were not
written in the English language, did not have human subjects, included patients without renal impairment,
were not randomized control trials, or were published more than eight years ago.
Results: Quintavalle et al9 performed a randomized control trial evaluating a single 80mg dose of atorvastatin
24 hours before percutaneous coronary intervention (PCI) or coronary angiography (CAG) vs placebo.
Results demonstrated incidence of CIN in 9 of 202 patients (4.5%) in the atorvastatin group and in 37 of 208
patients (17.8%) in the control group. Shehata and Hamza10 also performed a double-blind randomized
control trial evaluating the use of 80mg daily of atorvastatin vs placebo for 48 hours prior to PCI. The
incidence of CIN was 5 of 65 patients (7.7%) in the atorvastatin group compared to 13 of 65 patients (20%)
in the control group.
Conclusion: As demonstrated by both studies, a high loading dose of atorvastatin is significantly efficacious
in reducing the incidence of contrast-induced nephropathy in patients with mild to moderate chronic kidney
disease undergoing PCI or CAG.
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Abstract   
 
Background: Contrast-induced nephropathy (CIN) is a serious adverse event that certain 
patients experience as a result of a radiologic study performed with intravascular contrast media.  
The most at risk population includes patients with preexisting renal impairment.  Due to the lack 
of successful treatment for contrast-induced nephropathy and its potentially critical results, 
preventative strategies are imperative.  Though many approaches have been implemented, no 
universal standard protocol currently exists for the prevention of CIN in at-risk patients.  Recent 
research has demonstrated controversial results of the use of short-term statin therapy for 
prevention of CIN.  The aim of this systematic review is to evaluate the efficacy of atorvastatin 
in prevention of CIN in patients with renal impairment undergoing coronary angiography or 
percutaneous coronary intervention. 
 
Methods:  An exhaustive search of available medical literature from MEDLINE-Ovid, 
MEDLINE-PubMed, and Google Scholar was performed using the search terms “contrast-
induced nephropathy,” “acute kidney injury,” “statins,” “atorvastatin,” “HMG-CoA reductase 
inhibitors.” Studies were excluded if they were not written in the English language, did not have 
human subjects, included patients without renal impairment, were not randomized control trials, 
or were published more than eight years ago. 
 
Results: Quintavalle et al9 performed a randomized control trial evaluating a single 80mg dose 
of atorvastatin 24 hours before percutaneous coronary intervention (PCI) or coronary 
angiography (CAG) vs placebo.  Results demonstrated incidence of CIN in 9 of 202 patients 
(4.5%) in the atorvastatin group and in 37 of 208 patients (17.8%) in the control group.  Shehata 
and Hamza10 also performed a double-blind randomized control trial evaluating the use of 80mg 
daily of atorvastatin vs placebo for 48 hours prior to PCI.  The incidence of CIN was 5 of 65 
patients (7.7%) in the atorvastatin group compared to 13 of 65 patients (20%) in the control 
group.  
 
Conclusion:  As demonstrated by both studies, a high loading dose of atorvastatin is 
significantly efficacious in reducing the incidence of contrast-induced nephropathy in patients 
with mild to moderate chronic kidney disease undergoing PCI or CAG. 
 
Keywords:  Contrast-induced nephropathy, acute kidney injury, contrast-induced acute kidney 
injury, CIN, CIAKI, statins, atorvastatin, prevention, contrast, chronic kidney disease. 
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The Efficacy of Short-Term, High-Dose Atorvastatin in Prevention 
of Contrast Induced Nephropathy in Patients with Impaired Renal 
Function 
 
BACKGROUND 
 Contrast-induced nephropathy (CIN) is a form of acute kidney injury (AKI) that occurs in 
some patients who undergo radiologic studies that utilize iodinated contrast media. While the 
overall average occurrence of CIN is approximately 2%,1 comorbidities and risk factors greatly 
affect each patient’s likelihood of developing CIN. For example, among patients who are healthy 
and have no risk factors, the incidence of CIN is less than 1%. 2,3 In comparison, the incidence of 
contrast-induced nephropathy can be as high as 50% in patients with multiple risk factors4. 
 The pathophysiology of contrast-induced acute kidney injury (CIAKI) is not completely 
understood though multiple theories exist.  First, it is thought that the contrast agent causes 
alterations in endogenous vasodilators, such as nitric oxide and endothelin, resulting in 
medullary hypoxia due to renal vasoconstriction.  Another theory claims the contrast agent 
increases the viscosity resulting in decreased medullary blood flow as the small diameter vessels 
in the vasa recta cannot accommodate this thick fluid.  In addition, the hyperosmotic effect of the 
contrast inhibits water reabsorption resulting in swelling of the renal tubules which causes 
increased intrarenal pressure.  Due to this increase in pressure, both renal blood flow and 
glomerular filtration are decreased.  Third, it is hypothesized that contrast agents may have direct 
cytotoxic effects on the renal tubules as a result of the release of free radicals.   
 The most commonly used diagnostic criteria for contrast-induced nephropathy (CIN) is 
the observance of a serum creatinine increase of 25% or more or a greater than 0.49mg/dl from 
baseline within 24 to 48 hours of contrast administration.  In addition to these laboratory 
changes, clinical observations could include fatigue, poor appetite, dependent edema, orbital 
edema, dry or itchy skin, and changes in urine color or characteristics.  Other laboratory 
abnormalities could include hyperkalemia, hyperphosphatemia, and metabolic acidosis.   
 Multiple variables affect a patient’s probability of developing contrast-induced 
nephropathy.  In addition to accounting for each patient’s risk factors, the dosing and type of 
contrast being used must be taken into consideration.  The most accurate prediction of a patient’s 
probability of developing CIN is made based on a series of risk factors.  Mehran et al4 developed 
a risk stratification score that assigns points (1-5) for eight risk factors based on correlation of the 
comorbidity to the development of CIN.  The eight risk factors are: hypotension, intra-aortic 
balloon pump use, congestive heart failure, serum creatinine greater than 1.5 or decreased 
glomerular filtration rate (stratification of points based on level), age greater than 75, anemia, 
diabetes mellitus, and contrast volume.  Based upon the risk score, patients in the study were 
placed into four risk categories: low, moderate, high, and very high.  The risk score is very 
accurate at predicting occurrence rate in each population as demonstrated by the high correlation 
between the predicted occurrence rate and the actual occurrence rate in the studied population 
(figure 1).  Of these risk factors, decreased baseline renal function has the greatest influence on 
the patient’s probability of developing a contrast-induced acute kidney injury. 
 Though contrast-induced nephropathy most commonly resolves within five to ten days 
and less than one percent of affected patients will require acute hemodialysis, the renal injury can 
have lasting effects-especially for patients who had decreased renal function before the acute 
insult5,6,7. Patients who develop CIN have demonstrated longer average length of hospital stay, 
increased 5-year mortality rates, as well as increased  incidence of myocardial infarction than 
those patients who do not develop CIN 8. 
 Due to the lack of effective treatment options for contrast-induced nephropathy, efforts 
are being made to find better prevention methods to decrease the incidence of CIN.  Multiple 
therapies have been used in an attempt to prevent acute kidney injury in patients undergoing 
contrast imaging.  These include, but are not limited to: prehydration with saline both orally and 
intravenously, sodium bicarbonate, theophylline, n-acetylcysteine, and most recently statin 
therapy.  Though prevention recommendations have been established, no universal standard of 
practice currently exists for the prevention of CIN in patients with renal compromise.   
 HMG-CoA reductase inhibitors, more commonly referred to as “statins”, are medications 
that reduce synthesis of cholesterol in the liver. While these medications are most commonly 
used to treat dyslipidemias and hyperlipidemia in an attempt to reduce occurrence of acute 
coronary syndrome as well as other arterial insufficiency, recent research has found additional 
benefits to statin therapy. Statin therapy has demonstrated conflicting results in preventing 
contrast-induced nephropathy in patients with and without renal impairment. The purpose of this 
systematic review is to evaluate the efficacy of high-dose, short-term atorvastatin use in 
prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing 
coronary angiography or percutaneous coronary intervention. 
 
METHODS 
 An exhaustive search of available medical literature from MEDLINE-Ovid, MEDLINE-
PubMed, and Google Scholar was performed using the search terms “contrast-induced 
nephropathy,” “acute kidney injury,” “statins,” “atorvastatin,” and  “HMG-CoA reductase 
inhibitors”.  Studies were excluded if they were not written in the English language, did not have 
human subjects, included patients without renal impairment, included patients undergoing 
contrast studies other than percutaneous coronary intervention or coronary angiography, were not 
randomized control trials, or were published more than 8 years ago.   
RESULTS 
 Exhaustive search efforts, as described above, produced 38 articles. However, many 
articles evaluated the use of a high loading dose of atorvastatin in prevention of contrast-induced 
nephropathy in patients without renal impairment or in patients undergoing contrast studies other 
than CAG or PCI.  Once the search criteria were narrowed down to eliminate studies that 
included patients without renal impairment, only two studies9,10 met all inclusion criteria.  The 
first study9 was found using MEDLINE-Ovid, while the second10 was found using MEDLINE-
PubMed.  An exhaustive search of Google Scholar resulting in both previously mentioned 
studies with no further qualifying studies. See Table I. 
Quintavalle et al (2012) 
 This study9 was double-blinded with computer-generated assignment and compared two 
groups: one group received a single dose of 80mg of atorvastatin within 24 hours before 
injection of contrast, while the other group did not receive atorvastatin.  In addition to either 
atorvastatin or no atorvastatin, both groups received 1200 mg N-acetylcysteine by mouth twice 
daily on both the day before and the day of the performance of the contrast study, and both 
groups were hydrated with sodium bicarbonate solution in accordance with current 
recommendations for prevention of contrast-induced acute kidney injury.  All patients included 
in the study had baseline glomerular filtration rate of less than 60 ml/min/1.73m2.  Serum 
creatinine (sCr), serum cystatin C (sCyC), blood urea nitrogen (BUN), sodium and potassium 
were all measured the day before the contrast procedure and at 24 hours, 48 hours, and 1 week 
after contrast administration.9 
 In this particular study, contrast-induced acute kidney injury (CIAKI) was defined as an 
increase greater than 10% of serum cystatin C concentration within 24 hours of contrast 
exposure.  Secondary outcomes of serum creatinine increases of ≥0.5mg/dL or 25% from 
baseline were also evaluated. An increase in sCr ≥0.5mg/dL from baseline at 48 hours after 
contrast administration was observed in 7 of 202 patients (3.5%) in the atorvastatin group and in 
16 of 208 patients (7.7%) in the control group (P=0.085).  Also, an increase in sCr ≥25% from 
baseline at 48 hours after the contrast procedure was observed in 6 of 202 patients (3%) in the 
atorvastatin group and 14 of 208 patients (7%) in the control group (P=0.10).  The incidence of 
CIAKI as defined by >10% increase in sCyC occurred in 9 of 202 patients (4.5%) in the 
atorvastatin group and in 37 of 208 patients (17.8%) in the control group (P=0.005). 9 Relative 
risk reduction (RRR) varied between 0.545 to 0.747 and number needed to treat (NNT) values 
varied between 7.52 to 26.6 patients depending on the diagnostic criteria for CIN used. See Table 
II. 
Shehata and Hamza (2015) 
 This double-blinded randomized control trial10 compared two groups: one group who 
received 80mg of atorvastatin daily for 48 hours prior to contrast media injection and one group 
that was given placebo.  Both groups were also given isotonic saline for hydration in addition to 
1200mg N-acetylcysteine 24 hours before and after percutaneous coronary intervention.  Serum 
creatinine, estimated GFR, serum potassium and sodium were evaluated immediately prior to 
performance of PCI (baseline), 72 hours after, and 10 days after.  Contrast-induced nephropathy 
was defined as an increase of ≥ 0.5 mg/dL or ≥25% in serum creatinine from baseline. CIN 
occurred in 5 of 65 patients (7.7%) in the atorvastatin group compared to 13 of 65 patients (20%) 
in the control group (P<0.05).10 Relative risk reduction (RRR) with the use of atorvastatin was 
0.615 and the number needed to treat was 8.13 patients. See Table II. 
DISCUSSION 
 As demonstrated in these two studies, 9,10  a high loading dose of atorvastatin significantly 
decreases the incidence of contrast-induced nephropathy in patients with mild to moderate 
chronic kidney disease undergoing coronary angiography or percutaneous coronary intervention.  
Though both studies had relatively low incidence of CIN (ranging from 3-7%, 5-18%, and 7-
20% depending on the diagnostic criteria used and the study), the designs of both studies 
increase the validity of the results.  Both studies9,10 reduced the risk for bias by using computer-
generated randomization to carry out randomized control trials.  The control groups and 
experimental groups were almost identical in both studies in accordance with baseline renal 
function, age, cardiovascular risk factors, medications, and body mass index.  In addition, both 
studies reported identical contrast agents used in control and experimental groups with very 
similar contrast volumes.  Other variables, including prehydration dosage and agents as well as 
N-acetylcysteine use were standardized between groups.  Objective outcome data were measured 
which significantly decreases any risk for bias or compromised results.   
 The data analysis of the results of each study9,10 demonstrated significant relative risk 
reduction (0.545-0.747 depending on the diagnostic criteria used and the study) and markedly 
low numbers needed to treat (7.52-26.6 depending on the diagnostic criteria used and the study) 
with use of atorvastatin for the prevention of CIN (See Table II). It is important to note that the 
study performed by Quintavalle et al9 also evaluated in vitro outcomes to determine the extent of 
renal damage in each study group (atorvastatin vs no atorvastatin).  This study9 found that in 
addition to reducing the occurrence of CIAKI, a high loading dose of atorvastatin prevented 
contrast media-induced renal cell apoptosis by reducing stress kinases activation.  This cellular-
level examination adds further evidence of the efficacy of a high loading dose of atorvastatin in 
prevention of contrast-induced nephropathy. 
 Although variables were standardized within each study, a difference in contrast-induced 
nephropathy diagnostic criteria as well as prehydration technique did exist between studies.  
While Quintavalle et al9 used an increase of ≥10% increase in serum cystatin C within 24 hours 
of contrast injection as the criteria for diagnosing CIN, Shehata and Hamza10 used an increase of 
≥0.5mg/dL or ≥25% increase from baseline serum creatinine within 72 hours of contrast 
administration as the diagnostic criteria for CIN.  However, Quintavalle et al9 also measured 
secondary outcomes of increases in sCr consistent with the diagnostic criteria used in the study 
by Shehata and Hamza. 10 This allows for parallel comparison between results further increasing 
the validity.  Quintavalle et al9 used a sodium bicarbonate solution for prehydration, while 
Shehata and Hamza10 used a normal saline solution.  Both hydration techniques have been 
proven beneficial in comparison to a lack of hydration techniques prior to contrast imaging; 
however, it has not yet been established if one is superior to the other.  Regardless of the 
variance between methods used in each study, the protocol was standardized between the control 
group and atorvastatin therapy group in each study which further strengthens the results. 
 The benefit of using a high loading dose of atorvastatin prior to percutaneous coronary 
intervention or coronary angiography in patients with mild to moderate renal impairment is 
clearly demonstrated in these two studies. 9,10  However, multiple questions still exist.  For 
example, the optimal time frame for treatment with atorvastatin is not distinct.  While one 
study10 used two doses of 80mg of atorvastatin prior to contrast injection, the other study9 used a 
single dose.  While both studies demonstrated the efficacy of atorvastatin therapy, the question of 
the optimal dosing regimen remains.  In addition, each study used a combination of measures to 
prevent CIN, including hydration therapy and N-acetylcysteine administration.  Further research 
should focus on the optimal combination of therapies for the maximal preventive effect.  An 
especially important area of research would be the investigation of the efficacy of atorvastatin 
therapy without concomitant hydration in prevention of CIAKI.  This research would prove very 
beneficial in helping providers make clinical decisions regarding fluid-intolerant patients, such as 
those with uncontrolled or significant congestive heart failure, who require contrast imaging.  If 
atorvastatin alone is efficacious in preventing contrast-induced acute kidney injury, clinicians 
could avoid fluid-overloading patients who might not tolerate the additional intravascular 
volume well. 
 As HMG-CoA reductase inhibitors have become more widely and chronically used, a 
significant amount of research has been performed evaluating the benefits of stating therapy in 
addition to the risks.  Adverse reactions to statin therapy have occurred, though serious adverse 
effects are rare at 0.01%.11 More common adverse effects include gastrointestinal upset, myalgia, 
and muscle cramps.  With the cost of one 80mg atorvastatin pill being approximately $2.24,12 the 
potential benefit clearly outweighs the factors of risk and cost. 
 Both studies9,10 included in this systematic review evaluated the efficacy of atorvastatin 
in prevention of CIN in statin-naïve patients.  Considering the large population of patients who 
take statins chronically, it would be important to evaluate the efficacy of a high loading dose of 
atorvastatin (or the established statin) in prevention of CIN.  This would be especially valuable 
information considering the recent changes to cholesterol control guidelines outlined by ATP IV 
resulting in an increased number of patients receiving long-term statin therapy.  Though many 
questions remain, the most important aspects of atorvastatin therapy in prevention of CIAKI that 
should be investigated are: the efficacy of a high loading dose of atorvastatin without 
concomitant hydration in prevention of CIN, and the efficacy of a high loading dose of 
atorvastatin in prevention of CIN in patients who are chronically on statins. 
CONCLUSION 
 Though more research is needed to define the optimal regimen, it is apparent that a 
significant reduction in the development of CIN results from use of high-dose, short-term 
atorvastatin in patients with mild to moderate chronic kidney disease undergoing coronary 
angiography or percutaneous coronary intervention.  This evidence could prove especially vital 
to patients, such as those with congestive heart failure, who cannot tolerate the hydration 
protocol that is currently recommended.  Short-term atorvastatin therapy could provide an 
alternative measure for prevention of contrast-induced nephropathy in this particular population, 
as well as an additional preventative therapy for the general population.  With the risk of serious 
adverse effect with statin therapy being approximately 0.01%, the benefit of using atorvastatin 
for prevention of CIAKI highly outweighs the risk. With this evidence presented and the 
insignificant risk of adverse effect, those patients with mild to moderate chronic kidney disease 
should receive a high loading dose of atorvastatin prior to iodinated contrast media use. 
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Table I: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade Criteria Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
 
Quintavalle 
et al9 
 
RCT 
 
Not seriousa 
 
Not Serious 
 
Seriousb 
 
Not Serious 
 
Unlikely 
 
Large Magnitude 
of Effectc 
 
High 
Shehata and 
Hamza10 
 
RCT 
 
Not Serious 
 
Not Serious 
 
Not Serious 
 
Seriousd 
 
Unlikely 
 
Large Magnitude 
of Effecte 
 
High 
a The lack of placebo substitution in the control group risks compromise of blinding, but objective outcome measure makes variation in 
results due to lack of complete blinding very unlikely. 
b The subgroup of patients with stage IV or V CKD (GFR≤30 mL/min/1.73m2) did not demonstrate the same benefit as those with mild 
to moderate CKD.  This subgroup demonstrated a wide confidence interval with odds ratio 0.10-4.93 and a p value of 0.75. 
c The RR for this study is 0.253, with a NNT of 7.52 using sCyC increase (≥10%) as criteria for CIAKI diagnosis.  The RR for this 
study is 0.455, with a NNT of 23.8 using sCr increase (≥0.5 mg/dL) as criteria for CIN diagnosis.     
d The sample size for this study was only 130 patients with 65 in each group: control and experimental. 
e The RR for this study is 0.385, with a NNT of 8.13. 
 
 
 
 
 
Table II: Data Analysis of Reviewed Studies 
 
Study 
CIN Diagnostic 
Criteria 
Relative 
Risk 
(RR) 
Relative Risk 
Reduction 
(RRR) 
Absolute Risk 
Reduction 
(AR) 
Number 
Needed to 
Treat (NNT) 
Quintavalle 
et al9 
Increase in sCr 
≥0.5mg/dL from baseline 
within 48hrs of contrast 
administration 
0.455 0.545 0.042 23.8 
Quintavalle 
et al9 
Increase in sCr ≥25% 
from baseline within 
48hrs of contrast 
administration 
0.441 0.559 0.038 26.6 
Quintavalle 
et al9 
Increase in sCyC ≥10% 
from baseline within 
48hrs of contrast 
administration 
0.253 0.747 0.133 7.52 
Shehata 
and 
Hamza10 
Increase in sCr 
≥0.5mg/dL or ≥25% 
from baseline within 
48hrs of contrast 
administration 
0.385 0.615 0.123 8.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure I: Contrast-Induced Nephropathy Risk Score 
 
 
Figure I: The contrast-induced nephropathy risk score derived from the development dataset 
(prediction based on risk score) predicted this complication in the validation set (actual measured 
incidence). 
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